Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. METHODS: This was a phase Ib/II st...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Sallman, David A., DeZern, Amy E., Garcia-Manero, Guillermo, Steensma, David P., Roboz, Gail J., Sekeres, Mikkael A., Cluzeau, Thomas, Sweet, Kendra L., McLemore, Amy, McGraw, Kathy L., Puskas, John, Zhang, Ling, Yao, Jiqiang, Mo, Qianxing, Nardelli, Lisa, Al Ali, Najla H., Padron, Eric, Korbel, Greg, Attar, Eyal C., Kantarjian, Hagop M., Lancet, Jeffrey E., Fenaux, Pierre, List, Alan F., Komrokji, Rami S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wolters Kluwer Health 2021
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099410/
https://ncbi.nlm.nih.gov/pubmed/33449813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02341
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg